Inhibition	O
of	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
by	O
CD28	B-protein
signalling	O
in	O
human	B-cell_type
T-cells	I-cell_type
.	O

Co-stimulation	O
of	O
T-lymphocytes	B-cell_type
by	O
T-cell	B-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
occupancy	O
and	O
activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
molecule	I-protein
results	O
in	O
enhanced	O
proliferation	O
and	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
production	O
.	O

The	O
increase	O
in	O
IL-2	B-protein
gene	O
expression	O
triggered	O
by	O
CD28	B-protein
involves	O
a	O
kappa	B-DNA
B-like	I-DNA
sequence	I-DNA
in	O
the	O
5'-regulatory	B-DNA
region	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
called	O
CD28-responsive	B-DNA
element	I-DNA
.	O

Stimulation	O
of	O
T-cells	B-cell_type
by	O
agonistic	O
anti-CD28	B-protein
antibodies	I-protein
in	O
conjunction	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-	O
or	O
TcR	B-protein
-derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Here	O
we	O
report	O
that	O
CD28	B-protein
engagement	O
,	O
however	O
,	O
exerts	O
opposite	O
effects	O
on	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Whereas	O
anti-CD28	B-protein
together	O
with	O
PMA	O
increased	O
the	O
DNA	O
binding	O
and	O
trans-activation	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
PMA-induced	O
activation	O
of	O
AP-1	B-protein
was	O
significantly	O
suppressed	O
.	O

The	O
inhibitory	O
effect	O
exerted	O
by	O
anti-CD28	B-protein
was	O
observed	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
as	O
well	O
as	O
in	O
functional	O
reporter-gene	O
assays	O
.	O

These	O
results	O
suggest	O
that	O
the	O
two	O
transcription	B-protein
factors	I-protein
are	O
independently	O
regulated	O
and	O
may	O
perform	O
different	O
functions	O
during	O
T-cell	O
activation	O
.	O

Biochem	NULL
,	NULL
.	NULL

J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
302	NULL
,	NULL
119-123	NULL
(	NULL
Printed	NULL
in	NULL
Great	NULL
Britain	NULL
)	NULL
119	NULL
Inhibition	NULL
of	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
by	NULL
CD28	NULL
signalling	NULL
in	NULL
human	NULL
T-cells	NULL
Marek	NULL
LOS	NULL
,	NULL
Wulf	NULL
DROGE	NULL
and	NULL
Klaus	NULL
SCHULZE-OSTHOFF*	NULL
Division	NULL
of	NULL
Immunochemistry	NULL
,	NULL
Deutsches	NULL
Krebsforschungszentrum	NULL
,	NULL
D-69120	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
Co-stimulation	NULL
of	NULL
T-lymphocytes	NULL
by	NULL
T-cell	NULL
receptor	NULL
(	NULL
TcR	NULL
)	NULL
occupancy	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
CD28	NULL
surface	NULL
molecule	NULL
results	NULL
in	NULL
enhanced	NULL
proliferation	NULL
and	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
production	NULL
.	NULL

The	NULL
increase	NULL
in	NULL
IL-2	NULL
gene	NULL
expression	NULL
triggered	NULL
by	NULL
CD28	NULL
involves	NULL
a	NULL
«	NULL
B-like	NULL
sequence	NULL
in	NULL
the	NULL
5'-regulatory	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
called	NULL
CD28-responsive	NULL
element	NULL
.	NULL

Stimulation	NULL
of	NULL
T-cells	NULL
by	NULL
agonistic	NULL
anti-CD28	NULL
antibodies	NULL
in	NULL
conjunction	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
-	NULL
or	NULL
TcR-derived	NULL
signals	NULL
induces	NULL
the	NULL
enhanced	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
CD28	NULL
engagement	NULL
,	NULL
however	NULL
,	NULL
exerts	NULL
opposite	NULL
effects	NULL
on	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
.	NULL

Whereas	NULL
anti-CD28	NULL
together	NULL
with	NULL
PMA	NULL
increased	NULL
the	NULL
DNA	NULL
binding	NULL
and	NULL
trans-activation	NULL
activity	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
PMA-induced	NULL
activation	NULL
of	NULL
AP-1	NULL
was	NULL
significantly	NULL
suppressed	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
exerted	NULL
by	NULL
anti-CD28	NULL
was	NULL
observed	NULL
at	NULL
the	NULL
level	NULL
of	NULL
DNA	NULL
binding	NULL
as	NULL
well	NULL
as	NULL
in	NULL
functional	NULL
reporter-gene	NULL
assays	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
two	NULL
transcription	NULL
factors	NULL
are	NULL
independently	NULL
regulated	NULL
and	NULL
may	NULL
perform	NULL
different	NULL
functions	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

INTRODUCTION	NULL
Activation	NULL
of	NULL
T-lymphocytes	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
two	NULL
signals	NULL
which	NULL
are	NULL
provided	NULL
by	NULL
an	NULL
antigen-specific	NULL
stimulus	NULL
delivered	NULL
through	NULL
the	NULL
CD3-T	NULL
-cell	NULL
receptor	NULL
(	NULL
TcR	NULL
)	NULL
complex	NULL
and	NULL
an	NULL
antigen-independent	NULL
mechanism	NULL
referred	NULL
to	NULL
as	NULL
co-stimulation	NULL
[	NULL
1,2	NULL
]	NULL
.	NULL

Numerous	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
TcR	NULL
engagement	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
co-stimulation	NULL
may	NULL
induce	NULL
a	NULL
state	NULL
of	NULL
unresponsiveness	NULL
(	NULL
anergy	NULL
)	NULL
or	NULL
programmed	NULL
cell	NULL
death	NULL
(	NULL
apoptosis	NULL
)	NULL
(	NULL
reviewed	NULL
in	NULL
refs	NULL
.	NULL

[	NULL
1,2	NULL
]	NULL
)	NULL
.	NULL

A	NULL
major	NULL
co-stimulatory	NULL
signal	NULL
is	NULL
triggered	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
T-cell	NULL
surface	NULL
molecule	NULL
CD28	NULL
,	NULL
which	NULL
is	NULL
the	NULL
counter	NULL
structure	NULL
of	NULL
the	NULL
B7-1	NULL
and	NULL
B7-2	NULL
antigen	NULL
present	NULL
on	NULL
activated	NULL
B	NULL
cells	NULL
,	NULL
dendritic	NULL
cells	NULL
and	NULL
monocytes	NULL
[	NULL
3-5	NULL
]	NULL
.	NULL

CD28	NULL
is	NULL
expressed	NULL
on	NULL
almost	NULL
all	NULL
CD4*	NULL
and	NULL
about	NULL
50	NULL
%	NULL
of	NULL
CD8*	NULL
T-cells	NULL
.	NULL

Signalling	NULL
via	NULL
CD28	NULL
readily	NULL
synergizes	NULL
with	NULL
signals	NULL
through	NULL
the	NULL
CD3-TcR	NULL
for	NULL
increased	NULL
cytokine	NULL
production	NULL
and	NULL
cell	NULL
proliferation	NULL
[	NULL
6-9	NULL
]	NULL
.	NULL

CD28	NULL
functions	NULL
as	NULL
a	NULL
regulator	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
of	NULL
both	NULL
gene	NULL
transcription	NULL
and	NULL
mRNA	NULL
stabilization	NULL
.	NULL

The	NULL
transcriptional	NULL
stimulation	NULL
of	NULL
IL-2	NULL
expression	NULL
by	NULL
the	NULL
CD28	NULL
co-stimulus	NULL
is	NULL
controlled	NULL
by	NULL
a	NULL
«	NULL
B-like	NULL
cis-regulatory	NULL
element	NULL
(	NULL
CD28	NULL
regulatory	NULL
element	NULL
)	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
that	NULL
can	NULL
be	NULL
occupied	NULL
by	NULL
transcription	NULL
factors	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-	NULL
«	NULL
B	NULL
family	NULL
[	NULL
10,11	NULL
]	NULL
.	NULL

Co-stimulation	NULL
of	NULL
T-cells	NULL
with	NULL
agonistic	NULL
anti-CD28	NULL
antibodies	NULL
together	NULL
with	NULL
anti-CD3	NULL
or	NULL
agents	NULL
that	NULL
mimic	NULL
TcR-induced	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
results	NULL
in	NULL
increased	NULL
nuclear	NULL
amounts	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
[	NULL
12	NULL
]	NULL
.	NULL

The	NULL
major	NULL
biochemical	NULL
events	NULL
initiated	NULL
by	NULL
CD28	NULL
are	NULL
largely	NULL
unknown	NULL
.	NULL

Several	NULL
pieces	NULL
of	NULL
evidence	NULL
suggest	NULL
a	NULL
signal-transduction	NULL
pathway	NULL
that	NULL
is	NULL
distinct	NULL
from	NULL
the	NULL
TcR	NULL
[	NULL
3	NULL
]	NULL
.	NULL

CD28	NULL
signalling	NULL
is	NULL
resistant	NULL
to	NULL
treatment	NULL
with	NULL
the	NULL
immunosuppressant	NULL
cyclosporin	NULL
A	NULL
and	NULL
does	NULL
not	NULL
involve	NULL
protein	NULL
kinase	NULL
C	NULL
trans-location	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
has	NULL
been	NULL
observed	NULL
that	NULL
CD28	NULL
mediates	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
100	NULL
kDa	NULL
protein	NULL
[	NULL
13	NULL
]	NULL
and	NULL
activation	NULL
of	NULL
phosphatidylinositol-3	NULL
kinase	NULL
[	NULL
14	NULL
]	NULL
and	NULL
phospholipase	NULL
C	NULL
[	NULL
15	NULL
]	NULL
.	NULL

Activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
cytokines	NULL
and	NULL
other	NULL
agents	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
rely	NULL
on	NULL
the	NULL
intracellular	NULL
formation	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
and	NULL
redox-regulated	NULL
processes	NULL
[	NULL
16-18	NULL
]	NULL
.	NULL

Among	NULL
other	NULL
stimuli	NULL
,	NULL
CD28-mediated	NULL
activation	NULL
of	NULL
NF-KB	NULL
is	NULL
inhibited	NULL
by	NULL
antioxidant	NULL
compounds	NULL
,	NULL
such	NULL
as	NULL
N-acetylcysteine	NULL
and	NULL
dithio-carbamates	NULL
[	NULL
19	NULL
]	NULL
.	NULL

A	NULL
contribution	NULL
of	NULL
redox-regulated	NULL
processes	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
co-stimulation	NULL
via	NULL
CD28	NULL
leads	NULL
to	NULL
a	NULL
rapid	NULL
decrease	NULL
in	NULL
intracellular	NULL
thiols	NULL
[	NULL
19	NULL
]	NULL
(	NULL
M.	NULL
Los	NULL
,	NULL
W.	NULL
Droge	NULL
and	NULL
K.	NULL
Schulze-Osthoff	NULL
,	NULL
unpublished	NULL
work	NULL
)	NULL
.	NULL

Besides	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
another	NULL
widely	NULL
used	NULL
mediator	NULL
of	NULL
immediate-early	NULL
gene	NULL
expression	NULL
is	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
gene	NULL
expression	NULL
associated	NULL
with	NULL
various	NULL
growth	NULL
and	NULL
differentiation	NULL
processes	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

[	NULL
20	NULL
]	NULL
)	NULL
.	NULL

AP-1	NULL
is	NULL
composed	NULL
of	NULL
a	NULL
heterodimeric	NULL
complex	NULL
of	NULL
the	NULL
c-fos	NULL
and	NULL
c-jun	NULL
gene	NULL
products	NULL
and	NULL
is	NULL
activated	NULL
by	NULL
complex	NULL
mechanisms	NULL
consisting	NULL
of	NULL
transcriptional	NULL
and	NULL
post-translational	NULL
events	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
alterations	NULL
of	NULL
the	NULL
redox	NULL
state	NULL
may	NULL
exert	NULL
opposite	NULL
effects	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
activation	NULL
[	NULL
21,22	NULL
]	NULL
.	NULL

Several	NULL
antioxidants	NULL
,	NULL
which	NULL
largely	NULL
inhibited	NULL
phorbol	NULL
ester-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
increased	NULL
AP-1	NULL
activation	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
two	NULL
transcription	NULL
factors	NULL
may	NULL
be	NULL
oppositely	NULL
regulated	NULL
by	NULL
the	NULL
redox	NULL
state	NULL
of	NULL
the	NULL
cell	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
,	NULL
in	NULL
addition	NULL
,	NULL
CD28-triggered	NULL
signalling	NULL
differentially	NULL
affects	NULL
the	NULL
two	NULL
transcription	NULL
factors	NULL
.	NULL

Whereas	NULL
agonistic	NULL
anti-CD28	NULL
antibodies	NULL
synergized	NULL
with	NULL
phorbol	NULL
esters	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
in	NULL
contrast	NULL
,	NULL
DNA	NULL
binding	NULL
and	NULL
trans-activation	NULL
activity	NULL
of	NULL
AP-1	NULL
were	NULL
significantly	NULL
inhibited	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
and	NULL
reagents	NULL
The	NULL
human	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
(	NULL
subclone	NULL
JR	NULL
)	NULL
was	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
heat-inactivated	NULL
fetal-calf	NULL
serum	NULL
and	NULL
aritibiotics	NULL
.	NULL

CLB-CD28/1	NULL
,	NULL
an	NULL
IgG	NULL
,	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
human	NULL
CD28	NULL
,	NULL
was	NULL
provided	NULL
by	NULL
Dr.	NULL
van	NULL
Liet	NULL
(	NULL
Amsterdam	NULL
)	NULL
and	NULL
used	NULL
after	NULL
purification	NULL
by	NULL
Protein	NULL
G-Sepharose	NULL
chromatography	NULL
.	NULL

Phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
H	NULL
,	NULL
O	NULL
,	NULL
(	NULL
perhydrol	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

Abbreviations	NULL
used	NULL
:	NULL
TcR	NULL
,	NULL
T-cell	NULL
receptor	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
electrophoretic-mobility-shift	NULL
assay	NULL
;	NULL
TBS	NULL
,	NULL
Tris-buffered	NULL
saline	NULL
;	NULL
NF	NULL
,	NULL
nuclear	NULL
factor	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

120	NULL
M.	NULL
Los	NULL
,	NULL
W.	NULL
Drége	NULL
and	NULL
K.	NULL
Schulze-Osthoff	NULL
Acetyl-CoA	NULL
,	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
[	NULL
``	NULL
*CJchloramphenicol	NULL
were	NULL
obtained	NULL
from	NULL
Boehringer-Mannheim	NULL
and	NULL
Amersham	NULL
respectively	NULL
.	NULL

Oligonucleotides	NULL
and	NULL
plasmids	NULL
The	NULL
sequences	NULL
of	NULL
the	NULL
oligonucleotides	NULL
used	NULL
to	NULL
detect	NULL
the	NULL
DNA-binding	NULL
activities	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
were	NULL
as	NULL
follows	NULL
(	NULL
the	NULL
binding	NULL
sites	NULL
are	NULL
underlined	NULL
)	NULL
:	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
5-AGCTTCAGAG	NULL
GGGATTTCCGAGAGG-3	NULL
'	NULL
;	NULL
AP-1	NULL
,	NULL
S-AGCTTGAIGAGT-CAGCCGGATC-3	NULL
'	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
annealed	NULL
with	NULL
complementary	NULL
strands	NULL
containing	NULL
S'-overhanging	NULL
ends	NULL
and	NULL
labelled	NULL
using	NULL
Klenow	NULL
polymerase	NULL
and	NULL
[	NULL
«	NULL
-**P	NULL
]	NULL
JdCTP	NULL
.	NULL

The	NULL
labelled	NULL
probe	NULL
was	NULL
purified	NULL
from	NULL
free	NULL
nucleotides	NULL
on	NULL
push	NULL
columns	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
TRE2CAT	NULL
used	NULL
to	NULL
determine	NULL
AP-1-dependent	NULL
trans-activation	NULL
activity	NULL
was	NULL
generated	NULL
by	NULL
insertion	NULL
of	NULL
two	NULL
AP-1-binding	NULL
sites	NULL
5¢	NULL
to	NULL
the	NULL
tk	NULL
promoter	NULL
of	NULL
pBLCAT2	NULL
.	NULL

This	NULL
vector	NULL
contains	NULL
the	NULL
HSV	NULL
basal	NULL
tk	NULL
promoter	NULL
from	NULL
residues	NULL
-109	NULL
to	NULL
+51	NULL
linked	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
[	NULL
23	NULL
]	NULL
.	NULL

The	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
termed	NULL
NF-	NULL
«	NULL
B4CAT	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
[	NULL
17	NULL
]	NULL
.	NULL

It	NULL
contained	NULL
four	NULL
spaced	NULL
NF-	NULL
«	NULL
B-binding	NULL
motifs	NULL
upstream	NULL
of	NULL
the	NULL
tk	NULL
promoter	NULL
in	NULL
pBLCAT2	NULL
.	NULL

To	NULL
detect	NULL
non-specific	NULL
effects	NULL
on	NULL
CAT	NULL
expression	NULL
,	NULL
transfections	NULL
with	NULL
the	NULL
parent	NULL
vector	NULL
pBLCAT2	NULL
were	NULL
performed	NULL
.	NULL

Electrophoretic-mobility-shift	NULL
assay	NULL
(	NULL
e.m.s.a	NULL
.	NULL
)	NULL

Cells	NULL
were	NULL
stimulated	NULL
at	NULL
1x	NULL
10	NULL
%	NULL
/ml	NULL
with	NULL
PMA	NULL
(	NULL
25	NULL
ng/ml	NULL
!	NULL
)	NULL

or	NULL
anti-CD28	NULL
(	NULL
1.5	NULL
ug/ml	NULL
)	NULL
.	NULL

After	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
ice-cold	NULL
PBS	NULL
and	NULL
lysed	NULL
in	NULL
a	NULL
high-salt	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
400	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
mM	NULL
EGTA	NULL
,	NULL
20	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
1	NULL
%	NULL
Nonidet	NULL
P40	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
1	NULL
mM	NULL
phenylmethylsulphonyl	NULL
fluoride	NULL
and	NULL
0.01	NULL
%	NULL
aprotinin	NULL
.	NULL

After	NULL
10	NULL
min	NULL
of	NULL
incubation	NULL
on	NULL
ice	NULL
,	NULL
extracts	NULL
were	NULL
cleared	NULL
by	NULL
centrifugation	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
the	NULL
extracts	NULL
(	NULL
about	NULL
10	NULL
4g	NULL
of	NULL
crude	NULL
protein	NULL
;	NULL
determined	NULL
by	NULL
the	NULL
Bio-Rad	NULL
assay	NULL
kit	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B-	NULL
and	NULL
-specific	NULL
**P-labelled	NULL
oligonucleotides	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
20	NULL
wl	NULL
volume	NULL
containing	NULL
2-4	NULL
wl	NULL
of	NULL
extract	NULL
,	NULL
4	NULL
xl	NULL
of	NULL
5	NULL
x	NULL
binding	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
50	NULL
mM	NULL
KCl	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
2.5	NULL
mM	NULL
MgC	NULL
!	NULL

1	NULL
,	NULL
,	NULL
20	NULL
%	NULL
Ficoll	NULL
)	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
as	NULL
non-specific	NULL
competitor	NULL
DNA	NULL
,	NULL
2	NULL
g	NULL
of	NULL
BSA	NULL
and	NULL
10000-15000	NULL
c.p.m	NULL
.	NULL

of	NULL
the	NULL
labelled	NULL
oligonucleotide	NULL
.	NULL

After	NULL
30	NULL
min	NULL
of	NULL
the	NULL
binding	NULL
reaction	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
samples	NULL
were	NULL
loaded	NULL
on	NULL
a	NULL
4	NULL
%	NULL
non-denaturing	NULL
polyacrylamide	NULL
gel	NULL
and	NULL
run	NULL
in	NULL
45	NULL
mM	NULL
Tris-borate	NULL
,	NULL
1mM	NULL
EDTA	NULL
,	NULL
pH	NULL
8.0	NULL
.	NULL

For	NULL
specificity	NULL
controls	NULL
a	NULL
200-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
probe	NULL
was	NULL
applied	NULL
.	NULL

Transfections	NULL
and	NULL
CAT	NULL
assays	NULL
Transfections	NULL
were	NULL
performed	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
combined	NULL
with	NULL
chloroquine	NULL
treatment	NULL
.	NULL

Briefly	NULL
,	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
(	NULL
TBS	NULL
)	NULL
and	NULL
resuspended	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
TBS	NULL
containing	NULL
200	NULL
ug	NULL
of	NULL
DEAE-dextran	NULL
,	NULL
400	NULL
ug	NULL
of	NULL
chloroquine	NULL
and	NULL
5-15	NULL
4g	NULL
of	NULL
plasmid	NULL
DNA	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
frequent	NULL
agitation	NULL
.	NULL

After	NULL
30	NULL
min	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
TBS	NULL
and	NULL
resuspended	NULL
in	NULL
50	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
portions	NULL
of	NULL
batch-transfected	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
12-15	NULL
h	NULL
with	NULL
anti-CD28	NULL
(	NULL
1.5	NULL
ug/ml	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
25	NULL
ng/ml	NULL
)	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
three	NULL
freeze/thaw	NULL
cycles	NULL
and	NULL
measured	NULL
for	NULL
protein	NULL
content	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
determined	NULL
essentially	NULL
as	NULL
described	NULL
[	NULL
24	NULL
]	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
total	NULL
cell	NULL
protein	NULL
were	NULL
mixed	NULL
in	NULL
a	NULL
150	NULL
wl	NULL
volume	NULL
with	NULL
0.53	NULL
mM	NULL
acetyl-	NULL
CoA	NULL
and	NULL
2.2	NULL
kBq	NULL
of	NULL
[	NULL
'*CJchloramphenicol	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
8-12	NULL
h.	NULL
Acetylated	NULL
chloramphenicol	NULL
was	NULL
extracted	NULL
in	NULL
ethyl	NULL
acetate	NULL
,	NULL
resolved	NULL
on	NULL
t.l.c	NULL
.	NULL

plates	NULL
and	NULL
quantified	NULL
on	NULL
a	NULL
t.l.c	NULL
.	NULL

linear	NULL
analyser	NULL
.	NULL

RESULTS	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
PMA	NULL
.	NULL

At	NULL
90	NULL
min	NULL
after	NULL
treatment	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
analysed	NULL
by	NULL
e.m.s.a	NULL
.	NULL

with	NULL
an	NULL
NF-	NULL
«	NULL
B-	NULL
and	NULL
AP-1-specific	NULL
oligonucleotide	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
,	NULL
PMA	NULL
induced	NULL
«	NULL
B-specific	NULL
DNA-binding	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
unstimulated	NULL
cells	NULL
.	NULL

Co-treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
induced	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Incubation	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
PMA	NULL
,	NULL
however	NULL
,	NULL
resulted	NULL
in	NULL
no	NULL
or	NULL
only	NULL
a	NULL
weak	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
confirm	NULL
previous	NULL
reports	NULL
that	NULL
CD28	NULL
signals	NULL
synergize	NULL
with	NULL
the	NULL
phorbol	NULL
ester-	NULL
or	NULL
anti-CD3-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
[	NULL
10-12	NULL
]	NULL
.	NULL

As	NULL
CD28-induced	NULL
signalling	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
rely	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
pro-oxidant	NULL
conditions	NULL
and	NULL
to	NULL
be	NULL
inhibited	NULL
by	NULL
antioxidants	NULL
[	NULL
12	NULL
]	NULL
,	NULL
we	NULL
further	NULL
analysed	NULL
the	NULL
above	NULL
effects	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
H,0	NULL
,	NULL
.	NULL

Cells	NULL
treated	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
revealed	NULL
a	NULL
marked	NULL
stimulation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

This	NULL
DNA-binding	NULL
activity	NULL
was	NULL
slightly	NULL
enhanced	NULL
on	NULL
CD28	NULL
stimulation	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Compared	NULL
with	NULL
cells	NULL
incubated	NULL
without	NULL
H,0	NULL
,	NULL
,	NULL
-H	NULL
;	NULL
0	NULL
,	NULL
+H,0	NULL
,	NULL
g*	NULL
g*	NULL
8	NULL
&	NULL
8	NULL
.	NULL

5	NULL
C	NULL
9	NULL
ar	NULL
ar	NULL
S	NULL
0	NULL
ar	NULL
ar	NULL
&	NULL
~	NULL
&	NULL
C	NULL
208	NULL
Figure	NULL
1	NULL
-	NULL
Effect	NULL
of	NULL
PMA	NULL
,	NULL
anti-CD28	NULL
and	NULL
anti-CD28	NULL
+	NULL
PMA	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
NF-xB	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
stimulated	NULL
for	NULL
90	NULL
min	NULL
with	NULL
PMA	NULL
(	NULL
25	NULL
ng/m	NULL
!	NULL
)	NULL

,	NULL
with	NULL
and	NULL
without	NULL
anti-CD28	NULL
(	NULL
aCD28	NULL
;	NULL
1.5	NULL
g/m	NULL
!	NULL
)	NULL

.	NULL

H,0	NULL
,	NULL
(	NULL
100	NULL
M	NULL
;	NULL
lanes	NULL
5-8	NULL
)	NULL
was	NULL
added	NULL
15	NULL
min	NULL
before	NULL
cell	NULL
stimulation	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
analysed	NULL
by	NULL
e.m.s.a	NULL
.	NULL

using	NULL
a	NULL
*P-labelled	NULL
xB-specific	NULL
oligonucleotide	NULL
.	NULL

The	NULL
positic	NULL
:	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-DNA	NULL
complex	NULL
is	NULL
marked	NULL
by	NULL
an	NULL
arrowhead	NULL
.	NULL

Specificity	NULL
of	NULL
DNA	NULL
binding	NULL
was	NULL
veri	NULL
'	NULL
using	NULL
a	NULL
200-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
oligonucleotide	NULL
(	NULL
{	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

-H	NULL
;	NULL
,0	NULL
,	NULL
+H,0	NULL
,	NULL
Q	NULL
b	NULL
o	NULL
o	NULL
¢	NULL
¢	NULL
<	NULL
\O\	NULL
ab	NULL
¢	NULL
vx	NULL
'	NULL
b	NULL
6	NULL
&	NULL
6	NULL
?	NULL
)	NULL

\al	NULL
v-x	NULL
'	NULL
b	NULL
©	NULL
©	NULL
€	NULL
286	NULL
CP	NULL
C	NULL
D	NULL
>	NULL
-	NULL
a	NULL
_	NULL
«	NULL
»	NULL
«	NULL
#	NULL
#	NULL
a	NULL
»	NULL
«	NULL
us	NULL
Figure	NULL
2	NULL
-	NULL
Effect	NULL
of	NULL
PMA	NULL
,	NULL
anti-CD28	NULL
and	NULL
anti-CD28	NULL
+	NULL
PMA	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
AP-1	NULL
Cells	NULL
were	NULL
stimulated	NULL
as	NULL
described	NULL
in	NULL
Figure	NULL
1	NULL
.	NULL

AP-1	NULL
DNA	NULL
binding	NULL
was	NULL
analysed	NULL
in	NULL
cell	NULL
extracts	NULL
with	NULL
an	NULL
AP-1-specific	NULL
oligonucleotide	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
AP-1-specific	NULL
DNA	NULL
complex	NULL
is	NULL
marked	NULL
by	NULL
an	NULL
arrowhead	NULL
.	NULL

The	NULL
weak	NULL
additional	NULL
band	NULL
of	NULL
low	NULL
mobility	NULL
observed	NULL
in	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
and	NULL
7	NULL
represents	NULL
unspecific	NULL
protein	NULL
binding	NULL
or	NULL
an	NULL
AP-1	NULL
complex	NULL
of	NULL
different	NULL
heterodimer	NULL
composition	NULL
.	NULL

a_	NULL
1.5	NULL
h	NULL
3	NULL
h	NULL
6h	NULL
12	NULL
h	NULL
Figure	NULL
3	NULL
-	NULL
Time	NULL
course	NULL
of	NULL
induction	NULL
of	NULL
AP-1	NULL
DNA	NULL
binding	NULL
and	NULL
inhibition	NULL
by	NULL
anti-CD28	NULL
treatment	NULL
Cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
.	NULL

After	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
analysed	NULL
by	NULL
e.m.s.a	NULL
.	NULL

with	NULL
the	NULL
AP-1-specific	NULL
oligonucieotide	NULL
.	NULL

A	NULL
section	NULL
of	NULL
the	NULL
fluorogram	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
arrowhead	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
the	NULL
AP-1-specific	NULL
DNA	NULL
complex	NULL
.	NULL

co-treatment	NULL
of	NULL
cells	NULL
with	NULL
anti-CD28	NULL
and	NULL
PMA	NULL
under	NULL
pro-oxidant	NULL
conditions	NULL
resulted	NULL
in	NULL
a	NULL
further	NULL
enhancement	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
(	NULL
Figure	NULL
1	NULL
;	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
with	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Thus	NULL
these	NULL
findings	NULL
support	NULL
the	NULL
idea	NULL
that	NULL
PMA-	NULL
and	NULL
CD28-induced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
are	NULL
mediated	NULL
by	NULL
redox	NULL
processes	NULL
.	NULL

The	NULL
same	NULL
experimental	NULL
conditions	NULL
were	NULL
used	NULL
to	NULL
analyse	NULL
the	NULL
Inhibition	NULL
of	NULL
AP-1	NULL
by	NULL
CD28	NULL
signalling	NULL
121	NULL
Table	NULL
1	NULL
Effect	NULL
of	NULL
PMA	NULL
,	NULL
anti-CD28	NULL
and	NULL
anti-CD28	NULL
+	NULL
PMA	NULL
on	NULL
NF-xB-	NULL
and	NULL
AP-1-dependent	NULL
transactivation	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
transfected	NULL
with	NULL
NF-	NULL
«	NULL
B4CAT	NULL
,	NULL
a	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
controlled	NULL
by	NULL
four	NULL
NF-xB-binding	NULL
sites	NULL
,	NULL
or	NULL
the	NULL
AP-1-driven	NULL
CAT	NULL
plasmid	NULL
TREZCAT	NULL
.	NULL

At	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
the	NULL
indicated	NULL
agents	NULL
as	NULL
described	NULL
in	NULL
Figure	NULL
1	NULL
.	NULL

After	NULL
15	NULL
h	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
analysed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

Controls	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
parent	NULL
plasmid	NULL
pBLCAT2	NULL
.	NULL

The	NULL
results	NULL
show	NULL
a	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
independent	NULL
transfections	NULL
.	NULL

Acetylation	NULL
(	NULL
%	NULL
)	NULL
NF-	NULL
«	NULL
BA4CAT	NULL
TRE2CAT	NULL
pBLCAT2	NULL
~-	NULL
H202	NULL
Medium	NULL
KB	NULL
)	NULL
5.2	NULL
14	NULL
Anti-CD28	NULL
5.7	NULL
4.9	NULL
1.2	NULL
PMA	NULL
29.6	NULL
52.1	NULL
0.9	NULL
PMA	NULL
+	NULL
anti-CD28	NULL
47.1	NULL
344	NULL
1.3	NULL
+H,0	NULL
,	NULL
Medium	NULL
22.3	NULL
18.8	NULL
11	NULL
Anti-CD28	NULL
26.8	NULL
8.9	NULL
0.8	NULL
PMA	NULL
44.6	NULL
26.3	NULL
14	NULL
PMA	NULL
+	NULL
anti-CD28	NULL
57.6	NULL
10.9	NULL
1.2	NULL
effects	NULL
on	NULL
AP-1	NULL
activation	NULL
.	NULL

AP-1	NULL
DNA	NULL
binding	NULL
was	NULL
already	NULL
detectable	NULL
in	NULL
unstimulated	NULL
cells	NULL
but	NULL
was	NULL
significantly	NULL
inhibited	NULL
by	NULL
anti-CD28	NULL
treatment	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
PMA	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
AP-1	NULL
DNA	NULL
binding	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
however	NULL
,	NULL
co-stimulation	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
anti-CD28	NULL
decreased	NULL
phorbol	NULL
ester-induced	NULL
AP-1	NULL
activation	NULL
to	NULL
a	NULL
similar	NULL
level	NULL
to	NULL
that	NULL
in	NULL
unstimulated	NULL
cells	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
is	NULL
the	NULL
fact	NULL
that	NULL
changes	NULL
in	NULL
DNA	NULL
binding	NULL
were	NULL
not	NULL
observed	NULL
with	NULL
an	NULL
isotype-matched	NULL
control	NULL
antibody	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
of	NULL
anti-CD28	NULL
was	NULL
even	NULL
more	NULL
pronounced	NULL
under	NULL
pro-oxidant	NULL
conditions	NULL
.	NULL

H	NULL
,	NULL
O	NULL
,	NULL
induced	NULL
a	NULL
slight	NULL
increase	NULL
in	NULL
AP-1	NULL
DNA	NULL
binding	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
PMA	NULL
and	NULL
H	NULL
,	NULL
O	NULL
,	NULL
reproducibly	NULL
resulted	NULL
in	NULL
weaker	NULL
DNA	NULL
binding	NULL
than	NULL
stimulation	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
co-treatment	NULL
of	NULL
cells	NULL
with	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
under	NULL
pro-oxidant	NULL
conditions	NULL
resulted	NULL
in	NULL
an	NULL
almost	NULL
complete	NULL
inhibition	NULL
of	NULL
AP-1	NULL
DNA	NULL
binding	NULL
,	NULL
which	NULL
was	NULL
even	NULL
lower	NULL
than	NULL
in	NULL
unstimulated	NULL
cells	NULL
.	NULL

In	NULL
further	NULL
experiments	NULL
the	NULL
time	NULL
course	NULL
of	NULL
CD28-mediated	NULL
inhibition	NULL
of	NULL
PMA-induced	NULL
AP-1	NULL
activation	NULL
was	NULL
analysed	NULL
.	NULL

AP-1	NULL
DNA	NULL
binding	NULL
was	NULL
greatly	NULL
activated	NULL
1.5	NULL
h	NULL
after	NULL
PMA	NULL
treatment	NULL
,	NULL
reaching	NULL
a	NULL
plateau	NULL
within	NULL
3	NULL
h	NULL
(	NULL
Figure	NULL
3	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Thereafter	NULL
,	NULL
DNA-binding	NULL
activity	NULL
gradually	NULL
declined	NULL
.	NULL

Anti-CD28-mediated	NULL
inhibition	NULL
of	NULL
AP-1	NULL
DNA	NULL
binding	NULL
followed	NULL
a	NULL
slightly	NULL
different	NULL
kinetic	NULL
course	NULL
.	NULL

Inhibitory	NULL
effects	NULL
of	NULL
anti-CD28	NULL
were	NULL
observed	NULL
1.5	NULL
h	NULL
after	NULL
cell	NULL
treatment	NULL
,	NULL
but	NULL
were	NULL
maximal	NULL
after	NULL
3	NULL
h	NULL
(	NULL
Figure	NULL
3	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
CD28	NULL
activation	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
were	NULL
further	NULL
investigated	NULL
in	NULL
functional	NULL
trans-activation	NULL
experiments	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
CAT	NULL
reporter	NULL
constructs	NULL
under	NULL
the	NULL
control	NULL
of	NULL
either	NULL
four	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
(	NULL
NF-	NULL
«	NULL
B4CAT	NULL
)	NULL
or	NULL
two	NULL
AP-1-binding	NULL
sites	NULL
(	NULL
TRE2CAT	NULL
)	NULL
.	NULL

When	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD28	NULL
,	NULL
a	NULL
slight	NULL
increase	NULL
in	NULL
trans-activation	NULL
of	NULL
the	NULL
«	NULL
B	NULL
reporter	NULL
construct	NULL
was	NULL
induced	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Incubation	NULL
with	NULL
PMA	NULL
led	NULL
to	NULL
a	NULL
strong	NULL
enhancement	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
further	NULL
enhanced	NULL
on	NULL
co-treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
.	NULL

Similarly	NULL
to	NULL
the	NULL
results	NULL
from	NULL
the	NULL
e.m.s.a	NULL
.	NULL

,	NULL
H,0	NULL
,	NULL
triggered	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B-dependent	NULL
gene	NULL
expression	NULL
induced	NULL
under	NULL
pro-oxidant	NULL
conditions	NULL
was	NULL
further	NULL
122	NULL
M.	NULL
Los	NULL
,	NULL
W.	NULL
Droge	NULL
and	NULL
K.	NULL
Schulze-Osthoff	NULL
augmented	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
.	NULL
'	NULL

Under	NULL
the	NULL
same	NULL
conditions	NULL
,	NULL
contrasting	NULL
effects	NULL
were	NULL
observed	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
AP-l-regulated	NULL
CAT	NULL
plasmid	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

PMA	NULL
induced	NULL
a	NULL
more	NULL
than	NULL
tenfold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
,	NULL
whereas	NULL
anti-CD28	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

However	NULL
,	NULL
when	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
anti-CD28	NULL
and	NULL
PMA	NULL
,	NULL
a	NULL
significant	NULL
inhibition	NULL
of	NULL
AP-l-dependent	NULL
gene	NULL
expression	NULL
was	NULL
observed	NULL
in	NULL
comparison	NULL
with	NULL
cells	NULL
incubated	NULL
with	NULL
PMA	NULL
alone	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
the	NULL
previous	NULL
DNA-binding	NULL
experiments	NULL
,	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
CD28	NULL
stimulation	NULL
was	NULL
stronger	NULL
when	NULL
cells	NULL
were	NULL
kept	NULL
under	NULL
pro-oxidant	NULL
conditions	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

H	NULL
,	NULL
O	NULL
,	NULL
increased	NULL
AP-1	NULL
activation	NULL
,	NULL
which	NULL
was	NULL
suppressed	NULL
by	NULL
anti-CD28	NULL
.	NULL

Also	NULL
PMA-induced	NULL
AP-1	NULL
activation	NULL
was	NULL
markedly	NULL
inhibited	NULL
by	NULL
anti-CD28	NULL
under	NULL
these	NULL
conditions	NULL
.	NULL

To	NULL
examine	NULL
non-specific	NULL
effects	NULL
on	NULL
CAT	NULL
expression	NULL
,	NULL
control	NULL
experiments	NULL
with	NULL
the	NULL
basal	NULL
reporter	NULL
plasmid	NULL
PBLCAT2	NULL
were	NULL
performed	NULL
.	NULL

Expression	NULL
of	NULL
pBLCAT2	NULL
showed	NULL
virtually	NULL
no	NULL
responsiveness	NULL
towards	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
stimulation	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Therefore	NULL
both	NULL
DNA-binding	NULL
and	NULL
transactivation	NULL
experiments	NULL
reveal	NULL
that	NULL
anti-CD28	NULL
selectively	NULL
potentiates	NULL
PMA-induced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
but	NULL
exerts	NULL
inhibitory	NULL
effects	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
AP-1	NULL
.	NULL

DISCUSSION	NULL
The	NULL
present	NULL
study	NULL
shows	NULL
that	NULL
stimulation	NULL
of	NULL
T-cells	NULL
by	NULL
phorbol	NULL
ester	NULL
and	NULL
CD28	NULL
engagement	NULL
exerts	NULL
distinct	NULL
effects	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
.	NULL

Incubation	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
agonistic	NULL
anti-CD28	NULL
antibodies	NULL
largely	NULL
increased	NULL
PMA-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
as	NULL
reported	NULL
in	NULL
earlier	NULL
studies	NULL
[	NULL
10-12	NULL
]	NULL
.	NULL

Activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
essentially	NULL
involved	NULL
post-translational	NULL
mechanisms	NULL
and	NULL
was	NULL
not	NULL
suppressed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
transcriptional	NULL
inhibitors	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
stimulating	NULL
effect	NULL
of	NULL
both	NULL
agents	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
pro-oxidant	NULL
state	NULL
,	NULL
as	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
is	NULL
efficiently	NULL
blocked	NULL
by	NULL
diverse	NULL
antioxidant	NULL
substances	NULL
[	NULL
15-18	NULL
]	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
anti-CD28	NULL
induces	NULL
a	NULL
rapid	NULL
and	NULL
transient	NULL
decrease	NULL
in	NULL
intracellular	NULL
thiol	NULL
concentration	NULL
,	NULL
suggesting	NULL
that	NULL
oxidative	NULL
mechanisms	NULL
are	NULL
involved	NULL
[	NULL
18	NULL
]	NULL
(	NULL
M.	NULL
Los	NULL
,	NULL
W.	NULL
Drége	NULL
and	NULL
K.	NULL
Schulze-Osthoff	NULL
,	NULL
unpublished	NULL
work	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
AP-1	NULL
by	NULL
phorbol	NULL
esters	NULL
presumably	NULL
involves	NULL
a	NULL
separate	NULL
pathway	NULL
from	NULL
that	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
[	NULL
22	NULL
]	NULL
.	NULL

PMA-induced	NULL
AP-1	NULL
activation	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
rely	NULL
on	NULL
a	NULL
pro-oxidant	NULL
effect	NULL
because	NULL
it	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
antioxidants	NULL
,	NULL
and	NULL
is	NULL
even	NULL
suppressed	NULL
under	NULL
pro-oxidant	NULL
conditions	NULL
[	NULL
22	NULL
]	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
and	NULL
others	NULL
have	NULL
recently	NULL
reported	NULL
that	NULL
diverse	NULL
antioxidants	NULL
that	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
even	NULL
strongly	NULL
induce	NULL
AP-1	NULL
DNA	NULL
binding	NULL
and	NULL
trans-activation	NULL
activity	NULL
[	NULL
21,22	NULL
]	NULL
.	NULL

Hence	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
NF-KB	NULL
is	NULL
an	NULL
oxidant-inducible	NULL
factor	NULL
,	NULL
whereas	NULL
AP-1	NULL
can	NULL
be	NULL
regarded	NULL
as	NULL
an	NULL
antioxidant-responsive	NULL
transcription	NULL
factor	NULL
.	NULL

This	NULL
study	NULL
shows	NULL
that	NULL
effects	NULL
similar	NULL
to	NULL
those	NULL
produced	NULL
by	NULL
pro-oxidants	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
anti-CD28	NULL
increased	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
but	NULL
significantly	NULL
inhibited	NULL
AP-1	NULL
.	NULL

Therefore	NULL
these	NULL
data	NULL
further	NULL
suggest	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
two	NULL
transcription	NULL
factors	NULL
may	NULL
be	NULL
differentially	NULL
regulated	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
PMA-induced	NULL
AP-1	NULL
activation	NULL
could	NULL
be	NULL
caused	NULL
by	NULL
several	NULL
candidate	NULL
mechanisms	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

[	NULL
20	NULL
]	NULL
)	NULL
.	NULL

Engagement	NULL
of	NULL
the	NULL
CD28	NULL
molecule	NULL
provokes	NULL
oxidant	NULL
conditions	NULL
,	NULL
which	NULL
may	NULL
counteract	NULL
a	NULL
signal	NULL
provided	NULL
by	NULL
protein	NULL
kinase	NULL
C.	NULL
For	NULL
instance	NULL
,	NULL
oxidative	NULL
stress	NULL
or	NULL
other	NULL
CD28-induced	NULL
downstream	NULL
signals	NULL
such	NULL
as	NULL
tyrosine	NULL
phosphorylation	NULL
could	NULL
interfere	NULL
with	NULL
the	NULL
dephosphorylation	NULL
of	NULL
c-Jun	NULL
,	NULL
which	NULL
mediates	NULL
AP-1	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
phorbol	NULL
esters	NULL
[	NULL
25	NULL
]	NULL
.	NULL

Other	NULL
possible	NULL
explanations	NULL
may	NULL
include	NULL
CD28-induced	NULL
changes	NULL
in	NULL
AP-1	NULL
interaction	NULL
with	NULL
inhibitory	NULL
proteins	NULL
,	NULL
inhibition	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
synthesis	NULL
,	NULL
or	NULL
increased	NULL
synthesis	NULL
of	NULL
repressing	NULL
members	NULL
of	NULL
the	NULL
family	NULL
such	NULL
as	NULL
Jun	NULL
B	NULL
[	NULL
20,26	NULL
]	NULL
.	NULL

These	NULL
mechanisms	NULL
,	NULL
however	NULL
,	NULL
appear	NULL
unlikely	NULL
,	NULL
because	NULL
PMA-induced	NULL
AP-1	NULL
activation	NULL
does	NULL
not	NULL
depend	NULL
on	NULL
protein	NULL
synthesis	NULL
and	NULL
inhibition	NULL
by	NULL
anti-CD28	NULL
was	NULL
already	NULL
apparent	NULL
early	NULL
after	NULL
cell	NULL
treatment	NULL
.	NULL

Is	NULL
there	NULL
a	NULL
biological	NULL
relevance	NULL
to	NULL
these	NULL
observations	NULL
?	NULL

Efficient	NULL
activation	NULL
of	NULL
T-cells	NULL
requires	NULL
co-stimulatory	NULL
signals	NULL
resulting	NULL
in	NULL
the	NULL
increase	NULL
in	NULL
IL-2	NULL
production	NULL
and	NULL
cell	NULL
proliferation	NULL
[	NULL
2	NULL
]	NULL
.	NULL

TcR	NULL
signalling	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
these	NULL
stimuli	NULL
may	NULL
induce	NULL
a	NULL
long-lasting	NULL
state	NULL
of	NULL
unresponsiveness	NULL
(	NULL
anergy	NULL
)	NULL
or	NULL
programmed	NULL
cell	NULL
death	NULL
(	NULL
apoptosis	NULL
)	NULL
.	NULL

Both	NULL
processes	NULL
can	NULL
be	NULL
antagonized	NULL
by	NULL
anti-CD28	NULL
,	NULL
which	NULL
prevents	NULL
cell	NULL
death	NULL
and	NULL
restores	NULL
T-cell	NULL
responsiveness	NULL
[	NULL
2,3,27	NULL
]	NULL
.	NULL

In	NULL
some	NULL
ways	NULL
conflicting	NULL
with	NULL
our	NULL
results	NULL
,	NULL
it	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
that	NULL
anergized	NULL
cells	NULL
strongly	NULL
suppress	NULL
AP-1	NULL
activation	NULL
,	NULL
which	NULL
was	NULL
suggested	NULL
to	NULL
contribute	NULL
to	NULL
the	NULL
anergic	NULL
state	NULL
[	NULL
28	NULL
]	NULL
.	NULL

Other	NULL
authors	NULL
,	NULL
however	NULL
,	NULL
could	NULL
not	NULL
confirm	NULL
these	NULL
data	NULL
and	NULL
found	NULL
no	NULL
differences	NULL
in	NULL
induction	NULL
of	NULL
AP-1	NULL
on	NULL
re-stimulation	NULL
of	NULL
anergized	NULL
versus	NULL
resting	NULL
cells	NULL
[	NULL
29	NULL
]	NULL
.	NULL

In	NULL
studies	NULL
with	NULL
thymocytes	NULL
and	NULL
T-cells	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
,	NULL
apoptosis	NULL
induced	NULL
by	NULL
growth	NULL
factor	NULL
deprivation	NULL
or	NULL
incomplete	NULL
T-cell	NULL
activation	NULL
was	NULL
prevented	NULL
by	NULL
CD28	NULL
co-stimulation	NULL
[	NULL
30	NULL
]	NULL
.	NULL

Apoptosis	NULL
in	NULL
T-cells	NULL
is	NULL
an	NULL
active	NULL
process	NULL
requiring	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
[	NULL
31,32	NULL
]	NULL
.	NULL

Several	NULL
papers	NULL
have	NULL
reported	NULL
that	NULL
early	NULL
steps	NULL
of	NULL
apoptosis	NULL
are	NULL
accompanied	NULL
by	NULL
transcriptional	NULL
induction	NULL
of	NULL
the	NULL
AP-1	NULL
subunits	NULL
c-fos	NULL
and	NULL
c-jun	NULL
[	NULL
33,34	NULL
]	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
antisense	NULL
RNA	NULL
constructs	NULL
of	NULL
c-fos	NULL
and	NULL
c-jun	NULL
prevent	NULL
or	NULL
inhibit	NULL
cell	NULL
death	NULL
[	NULL
34	NULL
]	NULL
.	NULL

Thus	NULL
it	NULL
may	NULL
be	NULL
conceivable	NULL
that	NULL
,	NULL
in	NULL
cells	NULL
undergoing	NULL
apoptosis	NULL
,	NULL
CD28-induced	NULL
inhibition	NULL
of	NULL
AP-1	NULL
activation	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
rescuing	NULL
effect	NULL
of	NULL
this	NULL
co-stimulus	NULL
.	NULL

Future	NULL
experiments	NULL
therefore	NULL
need	NULL
to	NULL
reveal	NULL
whether	NULL
inhibition	NULL
of	NULL
AP-1	NULL
activation	NULL
by	NULL
CD28	NULL
interferes	NULL
with	NULL
apoptotic	NULL
processes	NULL
resulting	NULL
from	NULL
incomplete	NULL
T-cell	NULL
activation	NULL
.	NULL

We	NULL
thank	NULL
M.	NULL
Pach	NULL
,	NULL
S.	NULL
Henze	NULL
and	NULL
S.	NULL
Hoflinger	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
-	NULL
Steinman	NULL
,	NULL
R.	NULL
M.	NULL
and	NULL
Young	NULL
,	NULL
J.	NULL
W.	NULL
(	NULL
1991	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

3	NULL
,	NULL
361-372	NULL
2	NULL
-	NULL
Mueller	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Jenkins	NULL
,	NULL
M.	NULL
K.	NULL
and	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
445-480	NULL
3	NULL
-	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Clark	NULL
,	NULL
E.	NULL
A.	NULL
and	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
87	NULL
,	NULL
5031-5035	NULL
4	NULL
-	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
11	NULL
,	NULL
211-216	NULL
5	NULL
-	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Boriello	NULL
,	NULL
F.	NULL
,	NULL
Hodes	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Reiser	NULL
,	NULL
H.	NULL
,	NULL
Hathcock	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Laszlo	NULL
,	NULL
G.	NULL
,	NULL
McKnight	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Kim	NULL
,	NULL
J.	NULL
,	NULL
Du	NULL
,	NULL
L.	NULL
,	NULL
Lombard	NULL
,	NULL
0	NULL
.	NULL

B.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
and	NULL
Sharpe	NULL
,	NULL
A.	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
907-911	NULL
6	NULL
-	NULL
Hara	NULL
,	NULL
T.	NULL
,	NULL
Fu	NULL
,	NULL
S.	NULL
M.	NULL
and	NULL
Hansen	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

161	NULL
,	NULL
1513-1524	NULL
7	NULL
-	NULL
Martin	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Morishita	NULL
,	NULL
Y.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Beatty	NULL
,	NULL
I.	NULL
G.	NULL
and	NULL
Hansen	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

136	NULL
,	NULL
3282-3287	NULL
8	NULL
-	NULL
Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Emerson	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
and	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
86	NULL
,	NULL
1333-1337	NULL
9	NULL
-	NULL
Van	NULL
Lier	NULL
,	NULL
R.	NULL
A.	NULL
W.	NULL
,	NULL
Brouwer	NULL
,	NULL
M.	NULL
and	NULL
Aarden	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

18	NULL
,	NULL
167-172	NULL
10	NULL
-	NULL
Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Irving	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
251	NULL
,	NULL
313-316	NULL
11	NULL
-	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Geerts	NULL
,	NULL
M.	NULL
and	NULL
Aarden	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
14179-14182	NULL
12	NULL
-	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Tan	NULL
,	NULL
T.-H.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
and	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
90	NULL
,	NULL
1696-1700	NULL
13	NULL
-	NULL
Vandenberghe	NULL
,	NULL
P.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Fletcher	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Kamoun	NULL
,	NULL
M.	NULL
,	NULL
Turka	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Thompson	NULL
,	NULL
C.	NULL
B.	NULL
and	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
951-960	NULL
14	NULL
Ward	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Westwick	NULL
,	NULL
J.	NULL
,	NULL
Hall	NULL
,	NULL
N.	NULL
D.	NULL
and	NULL
Sansom	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
2572-2577	NULL
Inhibition	NULL
of	NULL
AP-1	NULL
by	NULL
CD28	NULL
signalling	NULL
123	NULL
Nunes	NULL
,	NULL
J.	NULL
,	NULL
Klasen	NULL
,	NULL
S.	NULL
,	NULL
Franco	NULL
,	NULL
M.-D.	NULL
,	NULL
Lipcey	NULL
,	NULL
C.	NULL
,	NULL
Mawas	NULL
,	NULL
C.	NULL
,	NULL
Bagnasco	NULL
,	NULL
M.	NULL
and	NULL
Olive	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

293	NULL
,	NULL
835-842	NULL
Schreck	NULL
,	NULL
R.	NULL
,	NULL
Rigber	NULL
,	NULL
P.	NULL
and	NULL
Basuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
2247-2258	NULL
Mihm	NULL
,	NULL
S.	NULL
,	NULL
Ennen	NULL
,	NULL
J.	NULL
,	NULL
Pessara	NULL
,	NULL
U.	NULL
,	NULL
Kurth	NULL
,	NULL
R.	NULL
and	NULL
Driige	NULL
,	NULL
W.	NULL
(	NULL
1991	NULL
)	NULL
AIDS	NULL
5	NULL
,	NULL
497-503	NULL
Schulze-Osthoff	NULL
,	NULL
K.	NULL
,	NULL
Beyaert	NULL
,	NULL
R.	NULL
,	NULL
Vandevoorde	NULL
,	NULL
V.	NULL
,	NULL
Haegeman	NULL
,	NULL
G.	NULL
and	NULL
Fiers	NULL
,	NULL
W.	NULL
(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
3095-3104	NULL
Costello	NULL
,	NULL
R.	NULL
,	NULL
Lipcey	NULL
,	NULL
C.	NULL
,	NULL
Algarté	NULL
,	NULL
M.	NULL
,	NULL
Cerdan	NULL
,	NULL
C.	NULL
,	NULL
Baguerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
and	NULL
Imbert	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
Growth	NULL
Diff	NULL
.	NULL

4	NULL
,	NULL
329-339	NULL
Angel	NULL
,	NULL
P.	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072	NULL
,	NULL
129-157	NULL
Schenk	NULL
,	NULL
H.	NULL
,	NULL
Klein	NULL
,	NULL
M.	NULL
,	NULL
Erdbriigger	NULL
,	NULL
W.	NULL
,	NULL
Driige	NULL
,	NULL
W.	NULL
and	NULL
Schulze-Osthoff	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
,	NULL
91	NULL
,	NULL
1672-1676	NULL
Meyer	NULL
,	NULL
M.	NULL
,	NULL
Schreck	NULL
,	NULL
R.	NULL
and	NULL
Baguerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
2005-2015	NULL
Luckow	NULL
,	NULL
B.	NULL
and	NULL
Schiitz	NULL
,	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15	NULL
,	NULL
5490	NULL
Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Moffat	NULL
,	NULL
L.	NULL
F.	NULL
and	NULL
Howard	NULL
,	NULL
B.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2	NULL
,	NULL
1044-1051	NULL
Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Defize	NULL
,	NULL
L.	NULL
H.	NULL
K.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Woodgett	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
and	NULL
Hunter	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
573-584	NULL
Received	NULL
25	NULL
January	NULL
1994/3	NULL
March	NULL
1994	NULL
;	NULL
accepted	NULL
9	NULL
March	NULL
1994	NULL
26	NULL
27	NULL
28	NULL
29	NULL
31	NULL
32	NULL
33	NULL
34	NULL
Auwerx	NULL
,	NULL
J.	NULL
and	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
983-993	NULL
Harding	NULL
,	NULL
F.	NULL
A.	NULL
,	NULL
McArthur	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Gross	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Raulet	NULL
,	NULL
D.	NULL
H.	NULL
and	NULL
Allison	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
356	NULL
,	NULL
607-609	NULL
Kang	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
A-C.	NULL
,	NULL
Brorson	NULL
,	NULL
K.	NULL
,	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
and	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
1134-1138	NULL
Go	NULL
,	NULL
C.	NULL
and	NULL
Miller	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1327-1336	NULL
Groux	NULL
,	NULL
H.	NULL
,	NULL
Torpier	NULL
,	NULL
G.	NULL
,	NULL
Monté	NULL
,	NULL
Y.	NULL
,	NULL
Capron	NULL
,	NULL
A.	NULL
and	NULL
Ameisen	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
331-340	NULL
Cohen	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

50	NULL
,	NULL
55-85	NULL
Smeyne	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Vendrell	NULL
,	NULL
M.	NULL
,	NULL
Hayard	NULL
,	NULL
M.	NULL
,	NULL
Baker	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Miao	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
Schilling	NULL
,	NULL
K.	NULL
,	NULL
Robertson	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
and	NULL
Morgan	NULL
,	NULL
J	NULL
.	NULL

1	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
363	NULL
,	NULL
166-169	NULL
Buttyan	NULL
,	NULL
R.	NULL
,	NULL
Zakeri	NULL
,	NULL
Z.	NULL
,	NULL
Lockshin	NULL
,	NULL
R.	NULL
and	NULL
Woigemuth	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

2	NULL
,	NULL
650-655	NULL
Colotta	NULL
,	NULL
F.	NULL
,	NULL
Polentarutti	NULL
,	NULL
N.	NULL
,	NULL
Sironi	NULL
,	NULL
M.	NULL
and	NULL
Mantovani	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
18278-18283	NULL

